Vir Biotechnology, Inc. (NASDAQ:VIR) Stock Has Consensus Price Target of $21.86 According to Brokerages

Vir Biotechnology, Inc. (NASDAQ:VIR) has earned an average recommendation of “Moderate Buy” from the nine research firms that are presently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $21.86.

A number of research analysts have weighed in on the stock. Wall Street Zen upgraded shares of Vir Biotechnology from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. HC Wainwright raised their target price on shares of Vir Biotechnology from $20.00 to $22.00 and gave the stock a “buy” rating in a report on Wednesday, October 7th. Zacks Research cut shares of Vir Biotechnology from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 6th. Morgan Stanley set a $25.00 price target on shares of Vir Biotechnology in a research note on Thursday, August 6th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Vir Biotechnology in a report on Friday, October 2nd.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of VIR. Fiduciary Financial Advisors purchased a new stake in shares of Vir Biotechnology in the second quarter worth approximately $29,000. Caxton Associates LLP purchased a new position in Vir Biotechnology during the 1st quarter valued at $112,000. Amundi boosted its holdings in Vir Biotechnology by 52.8% during the 1st quarter. Amundi now owns 15,315 shares of the company’s stock valued at $137,000 after acquiring an additional 5,294 shares during the period. Royal Bank of Canada grew its position in Vir Biotechnology by 223.1% in the 1st quarter. Royal Bank of Canada now owns 15,355 shares of the company’s stock valued at $138,000 after acquiring an additional 10,603 shares during the last quarter. Finally, Maryland State Retirement & Pension System grew its position in Vir Biotechnology by 19.8% in the 1st quarter. Maryland State Retirement & Pension System now owns 16,163 shares of the company’s stock valued at $145,000 after acquiring an additional 2,668 shares during the last quarter. Institutional investors own 65.32% of the company’s stock.

Vir Biotechnology Stock Performance

NASDAQ VIR opened at $11.57 on Friday. The company has a market cap of $1.96 billion, a P/E ratio of -6.22 and a beta of 1.59. The business’s 50 day moving average price is $10.81 and its 200-day moving average price is $9.40. Vir Biotechnology has a fifty-two week low of $4.82 and a fifty-two week high of $12.00.

Vir Biotechnology (NASDAQ:VIR) last released its quarterly earnings results on Wednesday, August 5th. The company reported $0.47 earnings per share for the quarter, beating the consensus estimate of $0.33 by $0.14. The company had revenue of $238.95 million for the quarter, compared to analysts’ expectations of $135.88 million. The business’s quarterly revenue was up 19582.5% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.80) EPS. As a group, equities analysts predict that Vir Biotechnology will post -1.84 EPS for the current year.

About Vir Biotechnology

Vir Biotechnology, Inc is a clinical-stage immunology company focused on developing medicines to prevent and treat serious infectious diseases and other immune-related conditions. The company uses antibody engineering, immunologic approaches and other technologies to identify and advance therapies designed to harness or modify the immune system.

Vir’s research and development programs have included treatments and vaccines for hepatitis B, human immunodeficiency virus (HIV), influenza and other infectious diseases.